Marketing-authorisation holder · Canada
Ipsen Biopharmaceuticals Canada Inc
18 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
18 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
18 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| CABOMETYX40 mg · Tablet | Cabozantinib | Canada | Marketed | 2018 |
| CABOMETYX60 mg · Tablet | Cabozantinib | Canada | Marketed | 2018 |
| CABOMETYX20 mg · Tablet | Cabozantinib | Canada | Marketed | 2018 |
| DYSPORT AESTHETIC300 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 2013 |
| DYSPORT THERAPEUTIC500 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 2017 |
| DYSPORT THERAPEUTIC300 unit / vial · Powder For Solution | Botulinum toxin | Canada | Marketed | 2017 |
| IQIRVO80 mg · Tablet | Elafibranor | Canada | Marketed | 2025 |
| OJEMDA100 mg · Tablet | Tovorafenib | Canada | Authorised | |
| OJEMDA25 mg / ml · Powder For Suspension | Tovorafenib | Canada | Authorised | |
| SOHONOS5 mg · Capsule | Palovarotene | Canada | Marketed | 2022 |
| SOHONOS1 mg · Capsule | Palovarotene | Canada | Marketed | 2022 |
| SOHONOS1.5 mg · Capsule | Palovarotene | Canada | Marketed | 2022 |
| SOHONOS2.5 mg · Capsule | Palovarotene | Canada | Marketed | 2022 |
| SOHONOS10 mg · Capsule | Palovarotene | Canada | Marketed | 2022 |
| SOMATULINE AUTOGEL120 mg / syr · Solution (Extended-Release) | Lanreotide | Canada | Marketed | 2007 |
| SOMATULINE AUTOGEL60 mg / syr · Solution (Extended-Release) | Lanreotide | Canada | Marketed | 2007 |
| SOMATULINE AUTOGEL90 mg / syr · Solution (Extended-Release) | Lanreotide | Canada | Marketed | 2007 |
| ONIVYDE4.3 mg / ml · Suspension | Irinotecan | Canada | Cancelled | 2017 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 18 | 17 | 1 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.